Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with chronic obstructive pulmonary disease (COPD)
S. Pascoe, C. Reynolds, W. Pleskow, S. Perry, A. Hmissi, L. Brookman (Horsham, United Kingdom; East Hanover, CA, United States Of America; Basel, Switzerland)
Source: Annual Congress 2007 - Mechanisms and new treatments of COPD
Session: Mechanisms and new treatments of COPD
Session type: Thematic Poster Session
Number: 2150
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Pascoe, C. Reynolds, W. Pleskow, S. Perry, A. Hmissi, L. Brookman (Horsham, United Kingdom; East Hanover, CA, United States Of America; Basel, Switzerland). Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 2007; 30: Suppl. 51, 2150
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001
Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001
A comparison of the effects of lung function between low dose theophylline and oral β2-agonist in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 215s Year: 2006
Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with asthma Source: Eur Respir J 2007; 30: Suppl. 51, 350s Year: 2007
Formoterol demonstrates bronchodilator efficacy in patients with reversible or poorly reversible chronic obstructive pulmonary disease (COPD), regardless of concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 177s Year: 2001
Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Source: Eur Respir J 2003; 21: 260-266 Year: 2003
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 74-81 Year: 2003
Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids Source: Eur Respir J 2001; 17: 337-342 Year: 2001
One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease Source: Eur Respir J 2004; 23: 241-249 Year: 2004
What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Source: Eur Respir J 2002; 19: 928-935 Year: 2002
The effect of oral corticosteroids on spirometric parameters in chronic obstructive pulmonary disease Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases Year: 2008
The efficacy and treatment length of oral corticosteroids in patient with acute exacerbation of chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 295s Year: 2005
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Source: Eur Respir J 2002; 19: 217-224 Year: 2002
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Source: Eur Respir J 2003; 21: 912 Year: 2003
Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004
The effect preoperative intervention with long-acting bronchodilator for untreated patients with obstructive lung disease Source: International Congress 2018 – Pharmacological management of COPD Year: 2018
Efficacy and cardiovascular safety of long-term bronchodilator therapy with theophylline in patients with chronic obstructive bronchitis (COB) Source: Eur Respir J 2003; 22: Suppl. 45, 52s Year: 2003
Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 146s Year: 2001
Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial Source: Eur Respir J 2002; 19: 936-943 Year: 2002
Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002